Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa.